ECHA Urges Registrants To Weigh Benefits/Risks Of REACH Authorization
This article was originally published in The Rose Sheet
Executive Summary
When all relevant factors are considered, firms may find that it’s not worth pursuing authorization for a substance of very high concern under REACH, European Chemicals Agency rep Richard Dubourg says. In any case, authorization is only temporary until an appropriate alternative presents itself.
You may also be interested in...
REACH Authorization Is Working, Says ECHA; Industry Remains Wary
ECHA has received one application for REACH authorization and is expecting about 10 more in the coming weeks, according to the agency. During a recent webinar, a chemical industry rep said firms are wary of uncertainties in the authorization process that make application a risky investment.
ECHA Should Commit To SVHC Substitution, Not SVHC Manufacturers – EEB
Speakers at ECHA’s eighth annual Stakeholders Day in Helsinki, representing the European Environmental Bureau and ECHA’s Risk Management Implementation division, address ECHA’s environmental and public-safety responsibilities and the risks involved in seeking authorization for substances of very high concern under European REACH law, respectively.
In Brief
While the so-called fiscal cliff has been avoided, sequestration still looms for FDA and other government agencies. The European Chemicals Agency updates its list of Substances of Very High Concern.